Oncotarget

Research Papers:

Estrogen regulates miRNA expression: implication of estrogen receptor and miR-124/AKT2 in tumor growth and angiogenesis

Cheng-Fei Jiang _, Dong-Mei Li, Zhu-Mei Shi, Lin Wang, Min-Min Liu, Xin Ge, Xue Liu, Ying-Chen Qian, Yi-Yang Wen, Lin-Lin Zhen, Jie Lin, Ling-Zhi Liu and Bing-Hua Jiang

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:36940-36955. https://doi.org/10.18632/oncotarget.9230

Metrics: PDF 1726 views  |   HTML 2636 views  |   ?  


Abstract

Cheng-Fei Jiang1,*, Dong-Mei Li1,*, Zhu-Mei Shi1,2,*, Lin Wang1, Min-Min Liu3, Xin Ge1, Xue Liu1, Ying-Chen Qian1, Yi-Yang Wen1, Lin-Lin Zhen3, Jie Lin4, Ling-Zhi Liu5, Bing-Hua Jiang1,5

1State Key Laboratory of Reproductive Medicine, Department of Pathology, Nanjing Medical University, Nanjing, China

2Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

3Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China

4Faculty of Software, Fujian Normal University, Fuzhou, China

5Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, USA

*These authors have contributed equally to this work

Correspondence to:

Bing-Hua Jiang, email: [email protected], [email protected]

Keywords: estrogen, miR-124, AKT2, breast cancer, estrogen receptors

Received: October 13, 2015    Accepted: April 16, 2016    Published: May 09, 2016

ABSTRACT

It is currently known that estrogen plays an important role in breast cancer (BC) development, but the underlying molecular mechanism remains to be elucidated. Accumulating evidence has revealed important roles of microRNAs in various kinds of human cancers, including BC. In this study, we found that among the microRNAs regulated by estrogen, miR-124 was the most prominent downregulated miRNA. miR-124 was downregulated by estradiol (E2) treatment in estrogen receptor (ER) positive BC cells, miR-124 overexpression suppressed cell proliferation, migration and invasion in BC cells; while the suppression of miR-124 using Anti-miR-124 inhibitor had opposite cellular functions. Under the E2 treatment, miR-124 had stronger effect to inhibit cellular functions in MCF7 cells than that in MDA-MB-231 cells. In addition, we identified that ERα, but not ERβ, was required for E2-induced miR-124 downregulation. Furthermore, AKT2, a known oncogene, was a novel direct target of miR-124. AKT2 expression levels were inversely correlated with miR-124 expression levels in human breast cancer specimens. AKT2 was overexpressed in BC specimens, and its expression levels were much higher in ERα positive cancer tissues than those ERα negative cancer tissues. Consistent with miR-124 suppression, E2 treatment increased AKT2 expression levels in MCF7 cells via ERα. Finally, overexpression of miR-124 in MCF7 cells significantly suppressed tumor growth and angiogenesis by targeting AKT2. Our results provide a mechanistic insight into a functional role of new ERα/miR-124/AKT2 signaling pathway in BC development. miR-124 and AKT2 may be used as biomarkers for ERα positive BC and therapeutic effect in the future.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9230